

Nigeria

Support for Vaccine: Yellow Fever

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Nigeria

2. **Vaccine grant number:** NGA-YF-C

3. **Date of Decision Letter:** 21 September 2020

4. **Date of the Partnership Framework Agreement:** 09 January 2014

5. **Programme title:** New Vaccine Support (NVS), Yellow Fever, Campaign

6. **Vaccine type:** Yellow Fever

7. **Requested product presentation and formulation of vaccine:**

YF, 10 doses/vial, lyophilised

8. **Programme duration:¹** 2013-2021

9. **Programme Budget (indicative):²** (subject to the terms of the Partnership Framework Agreement, if applicable)

	2013-2019	2020	2021	2022	2023	2024	Total ³
Programme Budget(US\$)	74,927,773	46,303,531	38,831,176	-	-	-	160,062,479

10. **Vaccine introduction grant:**

Not applicable

11. **Product switch grant:**

Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2013-2019	2020	2021
Number of vaccine doses	-	27,964,200	29,162,500
Number of AD syringes	-	29,694,300	28,899,800
Number of re-constitution syringes	-	3,296,100	3,207,900
Number of safety boxes	-	362,900	353,200
Annual Amounts (US\$)	74,927,773	35,420,000	37,436,928

13. Procurement agency: UNICEF Supply Division

14. Self-procurement:

Not applicable

15. Co-financing obligations:

Not applicable

16. Operational support for campaigns:

Year	Grant number	Amount (US\$)
2013	NGA-YF-C-OPS-MOH	6,495,000
2016	NGA-YF-C-OPS	822,202
2016	NGA-YF-C-OPS-UNIC	5,447,171
2016	NGA-YF-C-OPS-WHO	5,807,127
2019	NGA-YF-C-OPS	42,310
2019	NGA-YF-C-OPS-UNIC	3,819,240
2019	NGA-YF-C-OPS-WHO	4,585,441
2020	NGA-YF-C-OPS	10,940,761
2021	NGA-YF-C-OPS	11,022,370

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> ● vaccine stock levels including buffer stock, by end of March; ● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. ● Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>


18. Financial clarifications:

Not applicable

19. Other conditions:

The number of doses and presentation are subject to supply availability and potential prioritization. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

For Gavi
Signed by



Pascal Bijleveld, Director Country Support

22 September 2020